Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elena Ghiaur

Internal Medicine Owings Mills, MD Medical Doctor

NPI 1942227871 CMS profile 42934

10085 Red Run Blvd Ste 306, Owings Mills, MD 21117

Open in the dashboard

General payments

$3,305

164 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elena Ghiaur of Owings Mills, MD is reported in the CMS Open Payments database as having received $3,305 across 164 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,131 55
2024 General $692 34
2023 General $685 36
2022 General $500 29
2021 General $173 9
2019 General $125 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elena Ghiaur
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Elena Ghiaur were reported at $1,131. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Elena Ghiaur Internal Medicine median Middle half National median
2019 $125 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $173 $135 $37–$521 $132
2022 $500 $141 $42–$496 $149
2023 $685 $149 $45–$519 $160
2024 $692 $154 $47–$537 $164
2025 $1,131 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $615 30 payments
  2. Novo Nordisk Inc $598 25 payments
  3. Lilly USA, LLC $530 30 payments
  4. GlaxoSmithKline, LLC. $304 15 payments
  5. Pfizer Inc. $213 10 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $206 9 payments
  7. Merck Sharp & Dohme Corporation $147 9 payments
  8. Gilead Sciences, Inc. $138 7 payments
  9. Exact Sciences Corporation $134 7 payments
  10. Sanofi-Aventis U.S. LLC $90 5 payments
  11. Other $330 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,286 163 payments
  2. Education $19 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $523 21 payments
  2. MOUNJARO $425 24 payments
  3. RYBELSUS $417 21 payments
  4. BREZTRI $345 17 payments
  5. TRELEGY ELLIPTA $218 11 payments
  6. ZEPBOUND $213 11 payments
  7. FARXIGA $173 9 payments
  8. Cologuard Collection Kit $134 7 payments
  9. AREXVY $127 6 payments
  10. AIRSUPRA $118 5 payments
  11. Other $1,624 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 100 drugs

Part D claims

3,638

Median for Internal Medicine: 777

Drug cost

$442,142

Median for Internal Medicine: $73,373

Branded share of claims

24.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 86 $91,542
Ozempic Semaglutide Brand 45 $64,874
Jardiance Empagliflozin Brand 31 $49,749
Rybelsus Semaglutide Brand 23 $45,106
Xarelto Rivaroxaban Brand 19 $25,829
Mounjaro Tirzepatide Brand 19 $23,410
Trulicity Dulaglutide Brand 17 $22,383
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 16 $19,885
Breo Ellipta Fluticasone/Vilanterol Brand 27 $12,350
Januvia Sitagliptin Phosphate Brand 12 $12,140

The 10 drugs with the highest cost, of 100 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$65,572

Of which drugs: $7,122

Medicare patients

167

Average age 71

Services billed

1,020

144 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 37%
Depression 27%
Cancer 23%
Chronic kidney disease 22%
Ischemic heart disease 20%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 53 53 $4,336

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $94
$94 — —
RYBELSUS
  • Novo Nordisk Inc $64
$64 23 —
Ozempic
  • Novo Nordisk Inc $64
$64 45 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $60
$60 16 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $46
  • Lilly USA, LLC $11
$57 31 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record